Article
Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease.
Journal of the National Cancer Institute - 1 Sept 2024
Keane Fergus, Chou Joanne F, Walch Henry, Schoenfeld Joshua, Singhal Anupriya, Cowzer Darren, Harrold Emily, O'Connor Catherine A, Park Wungki, Varghese Anna, El Dika Imane, Balogun Fiyinfolu, Yu Kenneth H, Capanu Marinela, Schultz Nikolaus, Yaeger Rona, O'Reilly Eileen M
Abstract excerpt
BACKGROUND: Mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most common oncogene alteration in pancreatic ductal adenocarcinoma, and KRAS glycine to cystine substitution at codon 12 (G12C) mutations (KRAS G12Cmut) are observed in 1%-2%. Several inhibitors of KRAS G12C have recently demonstrated promise in solid tumors, including pancreatic cancer. Little is known regarding clinical, genomics, and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.